We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Qarziba

News List

Recordati to acquire EUSA Pharma to expand rare disease products portfolio Pharmaceutical-Technology
December 06, 2021
Italian company Recordati has signed an agreement to acquire EUSA Pharma in a deal worth about $848.9m (€750m) to expand its rare disease products portfolio.
SMC endorses EUSA Pharma’s Qarziba pharmatimes
November 14, 2018
A medicine used to treat a rare cancer that predominantly occurs in very young children is to be routinely funded on the NHS in Scotland.
NICE backs Qarziba for children with high-risk neuroblastoma pharmatimes
July 16, 2018
NHS funding for EUSA’s Pharma’s Qarziba has been approved to treat children with high-risk neuroblastoma.
Long-term benefit of Qarziba uncertain, says NICE pharmatimes
May 07, 2018
The National Institute for Health and Care Excellence has ruled against the provision of NHS funding for EUSA Pharma’s neuroblastoma treatment Qarziba.